11 maleimidoundecanoic acid

11-Maleimidoundecanoic acid is an alkyl chain-based PROTAC linker used in PROTAC synthesis (PROTAC is an acronym for [PROteolysis-TArgeting Chimera]).

MS 154 is a potent and selective cereblon-recruiting Degrader (PROTAC®) of mutant epidermal growth factor receptor (EGFR), comprising a cereblon-binding moiety joined by a linker to gefitinib(Iressa). MS 154 decreases EGFR protein levels, inhibits downstream signaling in and inhibits proliferation of mutant EGFR-bearing lung cancer cells (DC50values are 11 and 25 nM in HCC-827 and H3255 cells, respectively; Dmax> 95% at 50 nM), but not in WT-EGFR-bearing ovarian and lung cancer cells lines. Bioavailable in mice following ip administration.

11-Aminoundecanoic acid, an alkyl chain-based PROTAC linker, is employed in PROTAC synthesis.

Boc-11-aminoundecanoic acid is an alkyl ether-based PROTAC linker used in the synthesis of [MS432].

FC 11 is a highly potent focal adhesion Ki nase (FAK) PROTAC®Degrader (DC50 values are 40 to 370 pM depending on cell line), which is composed of the FAK inhibitor PF 562217 joined by a linker to the cereblon-binding ligand Pomalidomide. The effects of FC 11 are reversible upon compound wash out. FC 11 also degrades autophosphorylated FAK (pFAKtyr397), displaying near complete degradation after 3 hours at 100 nM in TM3 cells.

Azido-PEG11-alcohol, a PEG-based PROTAC linker, is utilized in PROTAC synthesis.

Azido-PEG11-azide is a PEG-based PROTAC linker used in PROTAC synthesis.

Boc-NH-PEG11-NH2 is a PEG-based PROTAC linker utilized in PROTAC synthesis.

Boc-NH-PEG11-OH, a PEG-based PROTAC linker, is utilized in PROTAC synthesis.

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) is a synthesized E3 ligase ligand-linker conjugate comprising a Thalidomide-based cereblon ligand and a linker.

m-PEG11-Br is a PEG-based PROTAC linker that can be utilized in the synthesis of PROTACs.

Propargyl-PEG11-methane is a PEG-based PROTAC linker utilized for the synthesis of PROTACs [1].

tert-Butyl 11-aminoundecanoate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

PROTAC ERRα ligand 2 is an inverse agonist for the estrogen-related receptor α (ERRα) with an IC50 of 5.67 nM.

CDK9-IN-11 is a potent CDK9 inhibitor and serves as the ligand for the PROTAC CDK9 Degrader-1 [1].

Amino-PEG11-amine, a polyethylene glycol (PEG)-based linker with 12 units, facilitates the conjugation of two mono diethylstilbestrol (DES)-based ligands. This strategy enhances the preparation of selective and potent estrogen receptor (ER) antagonists, offering an innovative approach for endocrine therapy in breast cancer treatment.

Amino-PEG11-OH is a non-cleavable, 11-unit PEG linker utilized in the synthesis of antibody-drug conjugates (ADCs) [1].

Azido-PEG11-amine, a PEG-based linker essential for PROTACs, connects two crucial ligands necessary for forming PROTAC molecules and enables selective protein degradation through the ubiquitin-proteasome system within cells.

Biotin-PEG11-amine is a PEG-based linker with biotin labeling which finds application in the synthesis of PROTACs[1].

HO-PEG11-OH, a PEG-based linker for PROTACs, connects two essential ligands necessary for forming PROTAC molecules, facilitating selective protein degradation via the ubiquitin-proteasome system within cells.

m-PEG11-Amino is a cleavable ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs)[1].

MS4078 is an inhibitor and aplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 19 nM for binding affinity to ALK.

Boc-NH-PEG2 (PROTAC Linker 11) is a polyethylene glycol (PEG)-based linker used in the synthesis of PROTACs. [1]

ACBI1 is a potent PROTAC degrader of BAF ATPase subunits SMARCA2 and SMARCA4, also degrades the polybromo-associated BAF (PBAF) complex member PBRM1, with DC50s of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively. ACBI1 is composed of a bromodomain ligand, a linker, and the E3 ubiquitin ligase VHL. ACBI1 can induce anti-proliferative effects and apoptosis.